The Stanford professor was a supporter of herd immunity during the COVID-19 pandemic.
President-elect Donald Trump announced that he has chosen Jay Bhattacharya, MD, PhD, to lead the National Institutes of Health (NIH),1 which is the leading medical research agency in the US. The news represents another major appointment in his administration to tackle health care, after tapping Robert F. Kennedy Jr for the secretary of HHS and Mehmet Oz, MD, to oversee CMS.
Bhattacharya currently works as a professor at Stanford University School of Medicine, identifying both as a physician and a health economist. He has worked formerly with the RAND Corporation and as a research fellow at the Hoover Institution. As leader of the NIH, he would work with Kennedy to direct the research that is conducted in the country.
NIH is a department that falls under HHS and is responsible for funding research on vaccines, cancer, and other diseases through different grants given to research institutions throughout the nation. Thousands of scientists also work with NIH directly to conduct research. All of these responsibilities could be led by Bhattacharya should he be confirmed by the Senate in January.
Bhattacharya is appointed as the nominee for director of the National Institutes of Health | Image credit: Grandbrothers - stock.adobe.com
Bhattacharya has had controversial opinions before this nomination. He was a coauthor of the Great Barrington Declaration that claimed that COVID-19 lockdowns were causing harm to the population in a way that could not be repaired. The paper was released in October 2020, before the first vaccination was available. The authors also called for herd immunity as the solution, with the idea that those at low risk should build immunity to COVID-19 by contracting the virus whereas those at high risk would be protected. The then-NIH director Francis Collins, MD, PhD, was a notable critic of this paper.
The professor from Stanford has also alleged that vaccine mandates that would disallow those unvaccinated from participating in the workplace or other activities undermined trust in the public health system for American citizens. Restrictions on social media have also followed Bhattacharya, who was a plaintiff in a case that alleged that federal officials suppressed conservative views on social media to combat misinformation, a case that he lost.
Alongside the nomination for the leader of NIH, Trump also announced his pick for the deputy secretary of HHS, Jim O’Neill. O’Neill is a former official in HHS, making him the sole nominee thus far with experience in the public health agencies. O’Neill will be in charge of improving management, transparency, and accountability in the HHS, according to Trump’s written statement.
These nominations come a couple weeks after Kennedy was named as Trump's pick for secretary of HHS. With the combination of Bhattacharya’s criticism of vaccine mandates alongside Kennedy’s public skepticism of vaccines,2 the Trump administration is making appointments that could change the way that vaccines are received in the US. Rapid adjustments to the way that vaccines are recommended and delivered would be challenging to enforce due to federal structures and regulatory practices. However, the positions on vaccines from the presumptive nominees could spell challenges to vaccine policy after the second Trump administration is sworn in on January 20, 2025.
References
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More